Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
OtherLetters: Comments and Responses

Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes

Response to Antonelli et al.

Marcin Skowroński, Dorota Zozulińska, Jacek Juszczyk, Bogna Wierusz-Wysocka
DOI: 10.2337/diacare.29.03.06.dc05-2263 Published 1 March 2006
Marcin Skowroński
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Dorota Zozulińska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Jacek Juszczyk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Bogna Wierusz-Wysocka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site

Response to Antonelli et al.

Antonelli et al. (1) classified diabetes associated with hepatitis C virus (HCV) infection as type 2. However, these patients show slightly different phenotype than typical type 2 diabetic subjects. Of interest, in our study, HCV diabetic patients presented similar intermediate clinical phenotype with significantly lower BMI (26.5 ± 4.8 vs. 30.9 ± 6.3 kg/m2), systolic (133.9 ± 14.0 vs. 142.9 ± 25.6 mmHg) and diastolic (84.4 ± 10.2 vs. 88.1 ± 16.0 mmHg) blood pressure, LDL cholesterol (1.9 ± 0.5 vs. 2.7 ± 0.8 mmol/l), and triglycerides (1.4 ± 0.8 vs. 2.6 ± 1.9 mmol/l). Furthermore, these patients showed lower C-reactive protein concentration (1.53 ± 1.23 vs. 3.54 ± 2.53 mg/l).

There is a groundswell of data now to link HCV infection with diabetes. However, serious doubt concerning the true character of diabetes in HCV patients must be emphasized. An autoimmune basis of the HCV-diabetes link is unlikely because no increased prevalence of β-cell autoimmune markers in HCV patients has been found (2). Nonetheless, there is a report of type 1 diabetes 1 year after blood transfusion–related HCV infection (3). Additionally, diabetic HCV patients with mixed cryoglobulinemia are more likely to carry non–organ-specific autoantibodies (4). Interestingly, there is evidence to support the hypothesis that HCV directly damages β-cells or disturbs their function, which ultimately leads to diabetes (5). Finally, there is no question that HCV, by itself, can induce insulin resistance, disturbing the insulin signaling pathway by the function of HCV core protein (6). Moreover, a crucial association between diabetes and the stage of fibrosis in HCV patients, independent of obesity and steatosis, on liver biopsy has also been demonstrated (6).

Diabetes in HCV patients has a unique and complex pathogenesis. Although both insulin resistance and β-cell dysfunction are responsible for the diabetes-HCV association, the specific nature of that link casts doubt on diagnosis of type 2 diabetes in these patients.

Footnotes

  • DIABETES CARE

References

  1. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E: Hepatitis C virus infection: evidence for an association with type 2 diabetes (Brief Report). Diabetes Care 28: 2548–2550, 2005
  2. Piquer S, Hernández C, Enriquez J, Ross A, Esteban JI, Genescà J, Bonifacio E, Puig-Domingo M, Simó R: Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 137: 38–42, 2001
  3. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD: Hepatitis C virus infection-related type 1 diabetes mellitus. Diabet Med 22: 340–343, 2005
  4. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E: Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology 43: 238–240, 2004
  5. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P: Hepatitis C virus infection and human pancreatic β-cell dysfunction (Brief Report). Diabetes Care 28: 940–941, 2005
  6. Knobler H, Schattner A: TNF-α, chronic hepatitis C and diabetes: a novel triad. Q J Med 98: 1–6, 2005

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.